Labsco announced that it will serve BioFire Diagnostics, a molecular biology affiliate of bioMérieux, a world leader in the field of in vitro diagnostics, as an exclusive sales agent partner in specified labs in the 48 contiguous US.

Market segments covered by Labsco will be small hospital laboratories and physician office laboratories as the FilmArray system is certified CLIA moderate complexity.

Labsco will be responsible for selling, account management, local marketing and contract presentation/execution for transition contracts and new contracts.

"With this strategic partnership, BioFire has placed its confidence in Labsco’s capabilities, which combines national reach with best-in-class technology, operational excellence and unmatched technical sales expertise," says Hank Struik, CEO of Labsco.

"As the leader in the molecular and syndromic diagnosis of infectious diseases, BioFire is the perfect partner for Labsco, and has demonstrated a commitment to excellence through their innovative FilmArray Technology line and focus on improving patient outcomes.

"Their innovative molecular diagnostics offer fits our exclusive clinical portfolio, which includes the industry’s leading technologies for chemistry, immunoassay, hematology, coagulation, blood gas and point of care diagnostics."

FilmArray is a CE-marked and FDA-cleared multiplex PCR system that is easy to use, accurate and rapid. Using a single reagent or panel, it identifies the most common disease-causing organisms responsible for a syndrome, whether they are viruses, bacteria, fungi or parasites.

FilmArray’s menu currently comprises three panels – respiratory, blood culture identification and gastrointestinal – all of which are CE-marked and FDA-cleared. Additionally, BioFire has submitted a de novo application to the FDA for its Meningitis-Encephalitis panel.